Outbreak of Salmonella enteritidis phage type 11B in the provinces of Alberta and Saskatchewan, June 2000.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to L Crowe.
Explore the source record for details and available documents.
BACKGROUND: The Dade Behring Syva(R) EMIT (enzyme multiplied immunoassay technique) method for the measurement of tacrolimus in whole blood was evaluated against the Abbott IMx(R) microparticle enzyme immunoassay (MEIA) method. EMIT measures tacrolimus colorimetrically, whereas MEIA measures the analyte using fluorimetry. Both methods incorporate a protein precipitation step prior to measurement. METHOD: Whole blood specimens were treated by two types of precipitation technique followed by analysis for tacrolimus by either MEIA or EMIT on the Bayer Advia 1650. Linearity and precision were assessed and correlation analysis performed to evaluate the EMIT assay on the Bayer Advia 1650. RESULTS: The EMIT tacrolimus assay was linear over the concentration range 0.0-22.0 micro g/L; the limit of detection was 1.2 micro g/L. Correlation between the Syva EMIT and IMx tacrolimus assays was excellent (r = 0.959) and no significant bias existed between the two methods (mean difference, delta = 0.221 micro g/L). Calibration data for the EMIT assay was stable for a period of 24-48 h on the Advia between runs. CONCLUSION: The Syva EMIT assay for the measurement of tacrolimus in whole blood is suited for daily routine use on the Bayer Advia 1650.
Explore the source record for details and available documents.
OBJECTIVE: To investigate lipid tolerance in sick, ventilator-dependent, very low birth weight infants from the first day of life and the effects of early introduction of intravenously administered lipid (IVL) on glucose homeostasis. METHOD: Twenty-nine infants in the neonatal intensive care unit with birth weight less than 1500 gm received isocaloric, isonitrogenous parenteral feedings from day 1 with either IVL, 1 gm/kg from day 1 to 3 gm/kg from day 4 (group I; n = 16), or IVL added only from day 8 (group II; n = 13). Possible adverse clinical effects were monitored. Blood metabolites, nonesterified fatty acids, serum triglycerides, and insulin levels were determined daily. Arterial blood gases were measured and changes in partial pressures of oxygen and of carbon dioxide in arterial blood were compared between the two groups. RESULTS: Early lipid infusion did not appear to have deleterious effects on blood gas tensions or to increase respiratory morbidity. The incidence of other adverse clinical effects that may be associated with IVL was not increased by earlier introduction of lipid. Serum lipid values were comparable to those of preterm infants receiving IVL at a later postnatal age. Blood glucose concentrations were higher in group II (mean, 7.50 (SEM 0.43) mmol/L) than in group I (mean, 6.01 (SEM 0.28) mmol/L; p less than 0.05). There was no evidence of increased gluconeogenesis in infants in group I and no correlation between blood glucose concentrations and serum nonesterified fatty acid concentrations. CONCLUSION: When given infusion rates not exceeding 0.15 gm/kg/hr, sick, very low birth weight infants can tolerate IVL with stepwise dose increases from the first day of life without an increased incidence of possible adverse effects.
Production of eicosanoids by deendothelialized aorta in response to continuous infusions of arachidonic acid and platelet suspensions was determined in a rabbit aorta perfusion model. 6-keto-PGF1 alpha production was stimulated by AA infusion in a dose-related manner. Infusion of AA at 4 micrograms/ml/min led to an initial production rate of 0.64 +/- 0.29 ng/min which gradually increased to 0.93 +/- 0.11 ng/min at the 20th min of infusion. When the concentration of AA infusion was increased to 10 micrograms/ml/min, 6-keto-PGF1 alpha production increased to 1.14 +/- 0.86 ng/min initially but declined with time. PGE2 production in response to AA 10 micrograms/min/ml was steady at around 5 ng/min while PGF2 alpha and TXB2 production were only slightly above the control. Perfusion of rabbit washed platelet suspensions at a rate of 3 X 10(8) plt/ml/min raised 6KPGF1 alpha production. The production was further increased when platelets were pretreated with 1-benzylimidazole (5 mM), along with a concurrent reduction in TXB2 release. Pretreatment of platelets with aspirin, on the other hand, abolished the increase in 6KPGF1 alpha production. Our data indicated that the vascular smooth muscle cells can efficiently utilize PGH2 produced by platelets to synthesize PGI2.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A successful support group for teenagers with type I diabetes requires more than informational lectures and discussions. Active learning by doing and the client's feeling of being in control are important. Attempts at gaining control require development of self-image, group solidarity, and the ability to communicate with nondiabetic peers and parents. Here is how one group did it.
Explore the source record for details and available documents.